SCHEMBL6835323

SCHEMBL6835323

CN1c2ccc(C(=O)O)cc2C(=O)C(Cc2cccc(Cl)c2)[S+]1[O-]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
PARK7 Q99497 1/20 0.39
NR4A2 P43354 1/20 0.38
KDM4C Q9H3R0 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 1/20 0.38
TAS2R14 Q9NYV8 2/20 0.38
MEN1 O00255 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
PLA2G2A P14555 1/20 0.37
HSD17B2 P37059 1/20 0.37
AKR1C3 P42330 1/20 0.37
PDE5A O76074 1/20 0.37
PRKAG1 P54619 1/20 0.36
PRKAA2 P54646 1/20 0.36
PRKAB1 Q9Y478 1/20 0.36
CCR2 P41597 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6835320 0.89 PARK7 (0.46) PARK7ALDH1A1MEN1HPGDKMT2A
SCHEMBL6835396 0.89 MRGPRX4 (0.37) PARK7ALDH1A1MEN1HPGDKMT2A
SCHEMBL6831719 0.88 NR4A2 (0.39) PARK7NR4A2KDM4CMAPTTAS2R14
SCHEMBL6831758 0.87 TSHR (0.39) PARK7KDM4CCCR2
SCHEMBL6831808 0.84 HTR7 (0.36) PARK7KDM4CALDH1A1KDM5B
SCHEMBL6835226 0.84 KDM5A (0.36) PARK7KDM4CKDM5B
SCHEMBL6837107 0.82 RXFP1 (0.48) ALDH1A1MAPTKMT2ANPC1RAB9A
SCHEMBL6680821 0.78 ALDH1A1 (0.41) RXRARXRBRXRGPARK7NR4A2
SCHEMBL6669286 0.78 ALDH1A1 (0.54) ALDH1A1MEN1HPGDKMT2ARAB9A
SCHEMBL6835347 0.77 RXRA (0.40) RXRARXRBRXRGNR4A2KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 RXRA 1763/4885RXRB 1654/4885RXRG 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.